According to Securities Star News, as of the close of trading on October 15, 2024, Walvax Biotech (300142) closed at 14.44 yuan, down 3.99%, with a turnover rate of 2.36%, a volume of 367,400 contracts and a turnover of 543 million yuan.
In terms of capital flow data on October 15, the net outflow of main funds was 43.6807 million yuan, accounting for 8.04% of the total turnover, the net inflow of floating funds was 21.4483 million yuan, accounting for 3.95% of the total turnover, and the net inflow of retail funds was 22.2323 million yuan, accounting for 4.09% of the total turnover.
The list of capital flows in the past 5 days is shown in the following table:
Walvax Biotech margin and securities lending information shows that in terms of financing, the financing purchase on the same day was 52.8875 million yuan, the financing repayment was 40.9176 million yuan, and the net financing purchase was 11.9699 million yuan. In terms of securities lending, 17,700 shares were sold by securities borrowing, 4,700.0 shares were repaid by securities borrowing, 115,300 shares were borrowed and borrowed, and the balance of securities borrowing and lending was 1,664,900 yuan. The balance of margin financing and securities lending was 2.217 billion yuan.
See the following table for a list of margin trading data in the past 5 days:
The main indicators and industry rankings of the stock are as follows:
Walvax's 2024 interim report shows that the company's main revenue was 1.433 billion yuan, a year-on-year decrease of 33.88%; net profit attributable to the parent company was 171 million yuan, a year-on-year decrease of 62.53%; deducted non-net profit of 146 million yuan, a year-on-year decrease of 65.39%; In the second quarter of 2024, the company's single-quarter main revenue was 834 million yuan, a year-on-year decrease of 37.53%; the net profit attributable to the parent company in a single quarter was 156 million yuan, a year-on-year decrease of 44.77%; The non-net profit deducted in a single quarter was 61.9566 million yuan, a year-on-year decrease of 78.46%; The debt ratio was 22.86%, the investment income was 3.6544 million yuan, the financial expenses were -27.7653 million yuan, and the gross profit margin was 80.0%. Walvax Biotech (300142) main business: engaged in the research and development, production and sales of biotechnology drugs such as human vaccines.
Explanation of the term capital flow: It refers to the reversal of the flow of funds through price changes. When the stock price is rising, the turnover generated by the active buy order is the force that drives the stock price up, which is defined as the inflow of funds, and the turnover generated by the active sell order when the stock price is in a falling state is the force that pushes the stock price down, and this part of the turnover is defined as the outflow of funds. The difference between the two on the day is the net force that is left to push the stock price up after the two forces offset on that day. The main capital flow, floating capital flow and retail capital flow are calculated by the transaction amount of each transaction order.
Note: The main funds are extra-large single transactions, the floating capital is large single transactions, and the retail investors are small and medium-sized single transactions
The above content is compiled by Securities Star based on public information, generated by intelligent algorithms, and does not constitute investment advice.